Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP5 | Q01469 | 6/20 | 0.61 |
| ▸ | FABP7 | O15540 | 4/20 | 0.61 |
| ▸ | FABP3 | P05413 | 3/20 | 0.61 |
| ▸ | SLC18A3 | Q16572 | 4/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.43 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15570630 | 1.00 | FABP5 (0.61) | FABP5FABP7FABP3SLC18A3SLC6A2 | |
| SCHEMBL19355090 | 1.00 | FABP5 (0.61) | FABP5FABP7FABP3SLC18A3SLC6A2 | |
| SCHEMBL19355194 | 1.00 | FABP5 (0.61) | FABP5FABP7FABP3SLC18A3SLC6A2 | |
| SCHEMBL19355089 | 1.00 | FABP5 (0.61) | FABP5FABP7FABP3SLC18A3SLC6A2 | |
| SCHEMBL4193266 | 1.00 | FABP5 (0.61) | FABP5FABP7FABP3SLC18A3SLC6A2 | |
| SCHEMBL7274841 | 0.97 | FABP5 (0.57) | FABP5FABP7FABP3SLC18A3SLC6A2 | |
| SCHEMBL8847691 | 0.87 | FABP5 (0.62) | FABP5FABP7FABP3SLC18A3SLC6A2 | |
| SCHEMBL25369792 | 0.86 | FABP5 (0.64) | FABP5FABP7FABP3SLC18A3SLC6A2 | |
| SCHEMBL21826667 | 0.86 | FABP5 (0.64) | FABP5FABP7FABP3SLC18A3SLC6A2 | |
| SCHEMBL21826668 | 0.86 | FABP5 (0.64) | FABP5FABP7FABP3SLC18A3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2887807-B1 | BENZIMIDAZOLE HEXAHYDROFURO[3,2-B]FURAN DERIVATIVES USEFUL AS AMP-ACTIVATED PROTEIN KINASE ACTIVATORS | MERCK SHARP & DOHME (US) | 2019-09-18 | — | — | EP | disclosed |
| EP-2888005-B1 | NOVEL AZABENZIMIDAZOLE HEXAHYDROFURO[3,2-B]FURAN DERIVATIVES | MERCK SHARP & DOHME (US) | 2019-04-03 | — | — | EP | disclosed |
| WO-2017156354-A1 | α-TRUXILLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2017-09-14 | — | — | WO | disclosed |
| US-9556193-B2 | Benzimidazole hexahydrofuro[3,2-b]furan derivatives | Merck Shapr & Dohme Corp. (US) | 2017-01-31 | — | — | US | disclosed |
| US-9290517-B2 | Azabenzimidazole hexahydrofuro[3,2-b]furan derivatives | MERCK SHARP & DOHME CORP. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20150284411-A1 | NOVEL AZABENZIMIDAZOLE HEXAHYDROFURO[E,2-B]FURAN DERIVATIVES | MERCK SHARP & DOHME LLC | 2015-10-08 | — | — | US | disclosed |
| US-20150218183-A1 | NOVEL BENZIMIDAZOLE HEXAHYDROFURO[3,2-B]FURAN DERIVATIVES | MERCK SHARP & DOHME LLC | 2015-08-06 | — | — | US | disclosed |
| EP-2888005-A1 | NOVEL AZABENZIMIDAZOLE HEXAHYDROFURO[3,2-B]FURAN DERIVATIVES | Merck Sharp & Dohme Corp. (US) | 2015-07-01 | — | — | EP | disclosed |
| EP-2887807-A1 | NOVEL BENZIMIDAZOLE HEXAHYDROFURO[3,2-B]FURAN DERIVATIVES | Merck Sharp & Dohme Corp. (US) | 2015-07-01 | — | — | EP | disclosed |
| WO-2014031468-A1 | NOVEL BENZIMIDAZOLE HEXAHYDROFURO[3,2-B]FURAN DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2014-02-27 | — | — | WO | disclosed |
| WO-2014031515-A1 | NOVEL AZABENZIMIDAZOLE HEXAHYDROFURO[3,2-B]FURAN DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2014-02-27 | — | — | WO | disclosed |
| US-20090018342-A1 | NEW EPOTHIOLONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION, AND THEIR PHARMACEUTICAL USE | KLAR ULRICH | 2009-01-15 | — | — | US | disclosed |
| US-7407975-B2 | Epothilone derivatives, method for producing same and their pharmaceutical use | BAYER SCHERING PHARMA AG (DE) | 2008-08-05 | — | — | US | disclosed |
| US-20060040990-A1 | Epothilone derivatives, process for their production, and their pharmaceutical use | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-02-23 | — | — | US | disclosed |
| US-7001916-B1 | Epothilon derivatives, method for the production and the use thereof as pharmaceuticals | SCHERING, AG (DE) | 2006-02-21 | — | — | US | disclosed |
| US-20030144523-A1 | EPOTHILONE DERIVATIVES, METHOD FOR PRODUCING SAME AND THEIR PHARMACEUTICAL USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2003-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218183-A1 | NOVEL BENZIMIDAZOLE HEXAHYDROFURO[3,2-B]FURAN DERIVATIVES | PRKAG3, PRKAG2, PRKAB2 | FABP5 126/4885FABP7 387/4885FABP3 30/4885 |
| US-20060040990-A1 | Epothilone derivatives, process for their production, and their pharmaceutical use | PTGIS, PTGES, PTGES2 | FABP5 2674/4885FABP7 3804/4885FABP3 4355/4885 |
| US-20030144523-A1 | EPOTHILONE DERIVATIVES, METHOD FOR PRODUCING SAME AND THEIR PHARMACEUTICAL USE | TUBB1, TUBA1C, TUBB4A | FABP5 4684/4885FABP7 4727/4885FABP3 4341/4885 |
| US-20150284411-A1 | NOVEL AZABENZIMIDAZOLE HEXAHYDROFURO[E,2-B]FURAN DERIVATIVES | PRKAG2, PRKAB2, PRKAG1 | FABP5 190/4885FABP7 507/4885FABP3 107/4885 |
| US-20090018342-A1 | NEW EPOTHIOLONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION, AND THEIR PHARMACEUTICAL USE | TUBB4A, TUBA1B, TUBB | FABP5 4776/4885FABP7 4843/4885FABP3 4531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.